CSI Market
Sign In | Register

Keenova Therapeutics Plc (MNK) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access MNK Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Keenova Therapeutics Plc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 26 2025) (Mar 28 2025) (Sep 27 2024)
Operating Activities
Income-113.50
Depreciation & amortization61.00
Amortization of Other Assets0.00
Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.60
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase-67.80
R & D, Environmental and Other Expense0.00
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal0.00
Share-based Compensation11.00
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Increasedecrease Opioidrelatedlitigationsettlementliability-
Increase Decrease Opioid Related Litigation Settlement Liability-
Inventory Step Up Amortization Related To Business Combination100.20
Inventory Step Up Amortization From Acquisitions-
Reorganization Items Noncash-
Amortization Accretion Expense On Debt Premium Discount And Settlement Obligation4.70
Increase Decrease In Accrued Consulting-
Increase Decrease Acthar Gel Related Litigation Settlement-
Income taxes3.60
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-54.10
Increase (Decrease) in Accounts Payable11.30
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital66.90
Other Noncash Income (Expense)-1.30
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.50
Discontinued operations0.00
Net Cash flow from Operating Activities23.10
Investing Activities
Capital Expenditures-10.40
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash Acquired From Business Acquisition-
Payments From Divestiture Of Business-
Proceeds from Sale of Restricted Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities5.90
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-4.50
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings-3.80
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-1.90
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-2,885.40
Cash Cash Equivalents and Restricted Cash Period Increase Decrease-
Cash and Cash Equivalents Including Restricted Cash Period End-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents965.70
Restricted Cash And Investments Current-
Restricted Cash And Investments Noncurrent-
Payments For Settlement Of Opioid Contingent Value Rights-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations954.00
Cash And Cash Equivalent Including Discontinued Operation824.90
Restricted Cash Current Including Discontinued Operations110.80
Restricted Cash Noncurrent Including Discontinued Operations30.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-5.70
Effect of exchange rate on cash flow-1.20
Discontinued operations0.00
Free Cash Flow12.70
Total Cash Flow11.70
4 historic quarters locked

Sign in to unlock the full Keenova Therapeutics Plc cash flow history.

Sign In Create Free Account

About Keenova Therapeutics Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 11, 2026
  • Source: mnk-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-055614

Figures are derived from filed reports and may be restated. Historical data is subject to revision.